Wednesday, October 7, 2015

News: New TRIGEN™ META-TAN™ Nail expands Smith & Nephew's femoral nail portfolio

Image result for smith and nephew
LONDON, Oct. 7, 2015 /PRNewswire/ -- Smith & Nephew (NYSE: SNN; LSE:SN), the global, medical technology business, today announced the launch of its TRIGEN META-TAN (Trochanteric Antegrade Nail) System at the Orthopaedic Trauma Association's (OTA) annual meeting in San Diego. The META-TAN System expands the clinically proven TRIGEN Nail portfolio with a versatile design that addresses a wide range of femoral fractures ranging from specific hip fractures to mid-shaft fractures and fractures near the knee.

For hip fractures in patients with good bone quality, the META-TAN System features the company's unique dual integrated screw design which is able to gain and maintain compression of the proximal femur. Additionally, the thinner size of the new nail may also benefit patients with narrow femoral canals.
For mid-shaft fractures and fractures near the knee, the variable bow of the nail provides versatile options for varying patient anatomy, and the multi-planar screw configuration allows for optimum fracture stability.
"High energy fractures in patients with good bone quality and less available space often pose challenges," says Dr. Daniel Chan of Georgia Orthopaedic Trauma Institute.  "META-TAN is an excellent solution as it does not require much bone removal with its smaller proximal body, while offering 'recon' compression capability when desired."
Surgeons attending this week's annual OTA meeting can learn more about the TRIGEN META-TAN System at the Smith & Nephew booth, #502. 
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic ReconstructionAdvanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than$4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

Trademark of Smith & Nephew. Registered US Patent and Trademark Office.
Published at PR Newswire

No comments:

Post a Comment